Literature DB >> 19172306

Bortezomib-related colon mucositis in a multiple myeloma patient.

Agostina Siniscalchi, Andrea Tendas, Micaela Ales, Stefano Fratoni, Luca Cupelli, Teresa Dentamaro, Laura Scaramucci, Marco Giovannini, Tommaso Caravita, Giuseppe Santeusanio, Pasquale Niscola, Paolo de Fabritiis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19172306     DOI： 10.1007/s00520-008-0573-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  9 in total

Review 1.  Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.

Authors:  Tommaso Caravita; Paolo de Fabritiis; Antonio Palumbo; Sergio Amadori; Mario Boccadoro
Journal:  Nat Clin Pract Oncol       Date:  2006-07

Review 2.  Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage.

Authors:  Joanne M Bowen; Rachel J Gibson; Adrian G Cummins; Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2006-02-02       Impact factor: 3.603

Review 3.  Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies.

Authors:  Rachel J Gibson; Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2006-04-08       Impact factor: 3.603

Review 4.  A practical update on the use of bortezomib in the management of multiple myeloma.

Authors:  Jesús San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Axel Glasmacher; Sundar Jagannath; Sagar Lonial; Robert Z Orlowski; Pieter Sonneveld; Heinz Ludwig
Journal:  Oncologist       Date:  2006-01

Review 5.  Mucositis in patients with hematologic malignancies: an overview.

Authors:  Pasquale Niscola; Claudio Romani; Luca Cupelli; Laura Scaramucci; Andrea Tendas; Teresa Dentamaro; Sergio Amadori; Paolo de Fabritiis
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

6.  Pseudomembranous colitis following bortezomib therapy in a myeloma patient.

Authors:  Sung-Jin Moon; Chang-Ki Min; Dong-Gun Lee; Seok Lee; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim; Myungshin Kim; Gyeongsin Park; Younggu Kim
Journal:  Acta Haematol       Date:  2007-01-18       Impact factor: 2.195

7.  Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Authors:  Sundar Jagannath; Bart Barlogie; James R Berenson; Seema Singhal; Raymond Alexanian; Gordan Srkalovic; Robert Z Orlowski; Paul G Richardson; Jessica Anderson; Darrell Nix; Dixie L Esseltine; Kenneth C Anderson
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

8.  Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.

Authors:  Vittorio Perfetti; Giovanni Palladini; Laura Brunetti; Adele Sgarella; Silvia Brugnatelli; Paolo G Gobbi; Gino Roberto Corazza
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-07       Impact factor: 2.566

Review 9.  Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment.

Authors:  Andrea M Stringer; Rachel J Gibson; Joanne M Bowen; Richard M Logan; Ann S-J Yeoh; Dorothy M K Keefe
Journal:  J Support Oncol       Date:  2007-06
  9 in total
  1 in total

Review 1.  Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

Authors:  Naoimh Herlihy; Roger Feakins
Journal:  United European Gastroenterol J       Date:  2022-05-28       Impact factor: 6.866
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.